UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB Number: 3235-0058
Expires: 06/30/94
Estimated average burden
hours per response .... 2.50
FORM 12-b-25
NOTIFICATION OF LATE FILING
SEC FILE NUMBER
0-22962
(Check One) Form 10-K [ ] Form 20-F[ ] Form 11-K[ ] Form 10-Q[X] Form N-SAR [ ]
For Period Ended: June 30, 1996
CUSIP NUMBER
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ X ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
- ---------------------------------------------------------------------------
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein. If the notification relates to a
portion of the filing of the filing checked above, identify the Item(s) to which
the notification relates: Item 6 and the Exhibits listed therein
PART I -- REGISTRANT INFORMATION
Full Name of Registrant
Human Genome Sciences, Inc.
- ---------------------------------------------------------------------------
Former Name if Applicable
- ---------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
9410 Key West Avenue
----------------------------------------------------------------------
City, State and Zip Code Rockville, MD 20850
-------------------------------------------------
PART II -- RULES 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25 (b), the following
should be completed. (Check box if applicable)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report of transition report on Form
10-Q, or portion thereof will be filed on or before the fifth calendar
day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-
25(c) has been attached if applicable.
<PAGE>
PART III -- NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period. (Attach Extra Sheets if Needed)
The Registrant has not yet finalized its redaction of the portions of the
exhibits to Form 10-Q for which confidential treatment is being requested.
Further review is required to make sure that the exhibits, as filed, will not
include portions of the agreements which it or its collaborators consider to be
confidential.
SEC 1344(11-91)
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Melvin D. Booth (301) 309-8504
--------------- ----- --------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports) been filed?
If answer is no, identify report(s). [X]Yes [ ]No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for that last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof? [ ]Yes [X]No
If so, attach an explanation of the anticipation change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
HUMAN GENOME SCIENCE, INC.
------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date August 15, 1996 By /s/ Melvin D. Booth
--------------- -------------------
Melvin D. Booth, President & Chief
Operating Officer and Acting
Chief Financial Officer
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
